Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi Sells 12,236 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 12,236 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total transaction of $44,049.60. Following the completion of the sale, the chief executive officer now directly owns 5,713,197 shares in the company, valued at approximately $20,567,509.20. The trade was a 0.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sight Sciences Trading Up 0.3 %

Shares of Sight Sciences stock opened at $3.32 on Thursday. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The firm has a market cap of $168.51 million, a PE ratio of -3.25 and a beta of 2.57. The business’s fifty day moving average is $3.89 and its two-hundred day moving average is $5.56. Sight Sciences, Inc. has a fifty-two week low of $3.20 and a fifty-two week high of $8.45.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The firm had revenue of $20.16 million during the quarter, compared to the consensus estimate of $20.41 million. Analysts anticipate that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on SGHT shares. Piper Sandler reiterated a “neutral” rating and issued a $5.50 price target (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Lake Street Capital cut Sight Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $10.00 to $5.00 in a report on Monday, November 4th. UBS Group started coverage on Sight Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $5.50 price target for the company. Citigroup decreased their price objective on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.12.

Institutional Trading of Sight Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Long Focus Capital Management LLC grew its position in Sight Sciences by 86.9% during the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock valued at $3,739,000 after acquiring an additional 260,594 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in shares of Sight Sciences in the 2nd quarter valued at about $1,234,000. Millrace Asset Group Inc. purchased a new stake in shares of Sight Sciences during the 3rd quarter worth about $874,000. State Street Corp increased its position in Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Sight Sciences by 46.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after buying an additional 65,767 shares during the period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.